9 results on '"Thomas Jr., Charles R."'
Search Results
2. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- Author
-
Verma, Vivek, Sprave, Tanja, Haque, Waqar, Simone, II, Charles B., Chang, Joe Y., Welsh, James W., and Thomas, Jr, Charles R.
- Published
- 2018
- Full Text
- View/download PDF
3. microRNA-451a regulates colorectal cancer proliferation in response to radiation
- Author
-
Ruhl, Rebecca, Rana, Shushan, Kelley, Katherine, Espinosa-Diez, Cristina, Hudson, Clayton, Lanciault, Christian, Thomas, Jr, Charles R., Liana Tsikitis, V., and Anand, Sudarshan
- Published
- 2018
- Full Text
- View/download PDF
4. "It wasn't as bad as I thought it would be": a qualitative study of early stage non-small cell lung cancer patients after treatment.
- Author
-
Golden, Sara E., Thomas Jr., Charles R., Deffebach, Mark E., Sukumar, Mithran S., Schipper, Paul H., Tieu, Brandon H., Kee, Andrew Y., Tsen, Andrew C., and Slatore, Christopher G.
- Subjects
- *
PATIENT-centered care , *MEDICAL communication , *THERAPEUTIC communication , *NON-small-cell lung carcinoma , *STEREOTACTIC radiotherapy , *PATIENTS - Abstract
Objective: While surgical resection is recommended for most patients with early stage lung cancer, stereotactic body radiotherapy (SBRT) is being increasingly utilized. Provider-patient communication regarding risks/benefits of each approach may be a modifiable factor leading to improved patient-centered outcomes. Our objective was to determine a framework and recommended strategies on how to best communicate with patients with early stage non-small cell lung cancer (NSCLC) in the post-treatment setting. We qualitatively evaluated the experiences of 11 patients with early clinical stage NSCLC after treatment, with a focus on treatment experience, knowledge obtained, communication, and recommendations. We used conventional content analysis and a patient-centered communication theoretical model to guide our understanding. Results: Five patients received surgery and six received SBRT. Both treatments were generally well-tolerated. Few participants reported communication deficits around receiving follow-up information, although several had remaining questions about their treatment outcome (mainly those who underwent SBRT). They described feeling anxious regarding their first surveillance CT scan and clinician visit. Overall, participants remained satisfied with care because of implicit trust in their clinicians rather than explicit communication. Communication gaps remain but may be addressed by a trusting relationship with the clinician. Patients recommend clinicians give thorough explanations and personalize when possible. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. IL-10 and integrin signaling pathways are associated with head and neck cancer progression.
- Author
-
Bornstein, Sophia, Schmidt, Mark, Choonoo, Gabrielle, Levin, Trevor, Gray, Joe, Thomas Jr., Charles R., Wong, Melissa, and McWeeney, Shannon
- Subjects
INTEGRINS ,HEAD & neck cancer ,CANCER invasiveness ,GENETIC mutation ,CHROMATIN - Abstract
Background: Head and neck cancer is morbid with a poor prognosis that has not significantly improved in the past several decades. The purpose of this study was to identify biological pathways underlying progressive head and neck cancer to inform prognostic and adjuvant strategies. We identified 235 head and neck cancer patients in The Cancer Genome Atlas (TCGA) with sufficient clinical annotation regarding therapeutic treatment and disease progression to identify progressors and non-progressors. We compared primary tumor gene expression and mutational status between these two groups. Results: 105 genes were differentially expressed between progressors and nonprogressors (FDR < 0.05). Pathway analyses revealed deregulation (FDR < 0.05) of multiple pathways related to integrin signaling as well as IL-10 signaling. A number of genes were uniquely mutated in the progressor cohort including increased frequency of truncating mutations in CTCF (P = 0.007). An 11-gene signature derived from a combination of unique mutations and differential expression was identified (PAGE4, SMTNL1, VTN, CA5A, C1orf43, KRTAP19-1, LEP, HRH4, PAGE5, SEZ6L, CREB3). This signature was associated with decreased overall survival (Logrank Test; P = 0.03443). Cox modeling of both key clinical features and the signature was significant (P = 0.032) with the greatest prognostic improvement seen in the model based on nodal extracapsular spread and alcohol use alone (P = 0.004). Conclusions: Molecular analyses of head and neck cancer tumors that progressed despite treatment, identified IL-10 and integrin pathways to be strongly associated with cancer progression. In addition, we identified an 11-gene signature with implications for patient prognostication. Mutational analysis highlighted a potential role for CTCF, a crucial regulator of long-range chromatin interactions, in head and neck cancer progression. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Comparison of measurement methods with a mixed effects procedure accounting for replicated evaluations (COM3PARE): method comparison algorithm implementation for head and neck IGRT positional verification.
- Author
-
Roy, Anuradha, Fuller, Clifton D., Rosenthal, David I., and Thomas Jr., Charles R.
- Subjects
IMAGE-guided radiation therapy ,MEDICAL imaging systems ,MEASUREMENT errors ,NECK injuries ,INFERIORITY complex - Abstract
Purpose: Comparison of imaging measurement devices in the absence of a gold-standard comparator remains a vexing problem; especially in scenarios where multiple, non-paired, replicated measurements occur, as in image-guided radiotherapy (IGRT). As the number of commercially available IGRT presents a challenge to determine whether different IGRT methods may be used interchangeably, an unmet need conceptually parsimonious and statistically robust method to evaluate the agreement between two methods with replicated observations. Consequently, we sought to determine, using an previously reported head and neck positional verification dataset, the feasibility and utility of a Comparison of Measurement Methods with the Mixed Effects Procedure Accounting for Replicated Evaluations (COM
3 PARE), a unified conceptual schema and analytic algorithm based upon Roy's linear mixed effects (LME) model with Kronecker product covariance structure in a doubly multivariate set-up, for IGRT method comparison. Methods: An anonymized dataset consisting of 100 paired coordinate (X/ measurements from a sequential series of head and neck cancer patients imaged near-simultaneously with cone beam CT (CBCT) and kilovoltage X-ray (KVX) imaging was used for model implementation. Software-suggested CBCT and KVX shifts for the lateral (X), vertical (Y) and longitudinal (Z) dimensions were evaluated for bias, inter-method (between-subject variation), intra-method (within-subject variation), and overall agreement using with a script implementing COM3 PARE with the MIXED procedure of the statistical software package SAS (SAS Institute, Cary, NC, USA). Results: COM3 PARE showed statistically significant bias agreement and difference in inter-method between CBCT and KVX was observed in the Z-axis (both p-value < 0.01). Intra-method and overall agreement differences were noted as statistically significant for both the X- and Z-axes (all p-value < 0.01). Using pre-specified criteria, based on intra-method agreement, CBCT was deemed preferable for X-axis positional verification, with KVX preferred for superoinferior alignment. Conclusions: The COM3 PARE methodology was validated as feasible and useful in this pilot head and neck cancer positional verification dataset. COM3 PARE represents a flexible and robust standardized analytic methodology for IGRT comparison. The implemented SAS script is included to encourage other groups to implement COM3 PARE in other anatomic sites or IGRT platforms. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. ACR Appropriateness Criteria Resectable Rectal Cancer.
- Author
-
Jones III, William E., Thomas Jr, Charles R., Herman, Joseph M., Abdel-Wahab, May, Azad, Nilofer, Blackstock, William, Das, Prajnan, Goodman, Karyn A., Hong, Theodore S., Jabbour, Salma K., Konski, Andre A., Koong, Albert C., Rodriguez-Bigas, Miguel, Small Jr, William, Zook, Jennifer, and Suh, W. Warren
- Subjects
- *
RECTAL cancer , *DRUG therapy , *DRUGS , *CANCER patients , *PHOTOTHERAPY - Abstract
The management of resectable rectal cancer continues to be guided by clinical trials and advances in technique. Although surgical advances including total mesorectal excision continue to decrease rates of local recurrence, the management of locally advanced disease (T3-T4 or N+) benefits from a multimodality approach including neoadjuvant concomitant chemotherapy and radiation. Circumferential resection margin, which can be determined preoperatively via MRI, is prognostic. Toxicity associated with radiation therapy is decreased by placing the patient in the prone position on a belly board, however for patients who cannot tolerate prone positioning, IMRT decreases the volume of normal tissue irradiated. The use of IMRT requires knowledge of the patterns of spreads and anatomy. Clinical trials demonstrate high variability in target delineation without specific guidance demonstrating the need for peer review and the use of a consensus atlas. Concomitant with radiation, fluorouracil based chemotherapy remains the standard, and although toxicity is decreased with continuous infusion fluorouracil, oral capecitabine is non-inferior to the continuous infusion regimen. Additional chemotherapeutic agents, including oxaliplatin, continue to be investigated, however currently should only be utilized on clinical trials as increased toxicity and no definitive benefit has been demonstrated in clinical trials. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every two years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Novel low-kVp beamlet system for choroidal melanoma.
- Author
-
Esquivel Jr., Carlos, Fuller, Clifton D., Waggener, Robert G., Wong, Adrian, Meltz, Martin, Blough, Melissa, Eng, Tony Y., and Thomas, Jr., Charles R.
- Subjects
CHOROID ,MELANOMA ,RADIOTHERAPY ,CANCER radiotherapy ,RADIATION doses ,ONCOLOGY ,CANCER - Abstract
Background: Treatment of choroidal melanoma with radiation often involves placement of customized brachytherapy eye-plaques. However, the dosimetric properties inherent in sourcebased radiotherapy preclude facile dose optimization to critical ocular structures. Consequently, we have constructed a novel system for utilizing small beam low-energy radiation delivery, the Beamlet Low-kVp X-ray, or "BLOKX" system. This technique relies on an isocentric rotational approach to deliver dose to target volumes within the eye, while potentially sparing normal structures. Methods: Monte Carlo N-Particle (MCNP) transport code version 5.0(14) was used to simulate photon interaction with normal and tumor tissues within modeled right eye phantoms. Five modeled dome-shaped tumors with a diameter and apical height of 8 mm and 6 mm, respectively, were simulated distinct positions with respect to the macula iteratively. A single fixed 9 × 9 mm2 beamlet, and a comparison COMS protocol plaque containing eight I-125 seeds (apparent activity of 8 mCi) placed on the scleral surface of the eye adjacent to the tumor, were utilized to determine dosimetric parameters at tumor and adjacent tissues. After MCNP simulation, comparison of dose distribution at each of the 5 tumor positions for each modality (BLOKX vs. eye-plaque) was performed. Results: Tumor-base doses ranged from 87.1-102.8 Gy for the BLOKX procedure, and from 335.3-338.6 Gy for the eye-plaque procedure. A reduction of dose of at least 69% to tumor base was noted when using the BLOKX. The BLOKX technique showed a significant reduction of dose, 89.8%, to the macula compared to the episcleral plaque. A minimum 71.0 % decrease in dose to the optic nerve occurred when the BLOKX was used. Conclusion: The BLOKX technique allows more favorable dose distribution in comparison to standard COMS brachytherapy, as simulated using a Monte Carlo iterative mathematical modeling. Future series to determine clinical utility of such an approach are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
9. Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapy.
- Author
-
Jones, Kristin, Fuller, Clifton D., Luh, Join Y., Childs, Craig C., Miller, Alexander R., Tolcher, Anthony W., Herman, Terence S., and Thomas Jr, Charles R.
- Subjects
DERMIS tumors ,RADIOTHERAPY ,TUMORS ,SKIN ,THERAPEUTICS - Abstract
Background: Keloids are common benign tumors of the dermis, typically arising after insult to the skin. While typically only impinging on cosmesis, large or recurrent keloids may require therapeutic intervention. While no single standardized treatment course has been established, several series report excellent outcomes for keloids with post-surgery radiation therapy. Case presentation: We present a patient with a history of recurrent keloids arising in the absence of an ascribed trauma and a maternal familial history of keloid formation, whose physical examination several large perineal keloids of 6-20 cm in the largest dimension. The patient was treated with surgical extirpation and adjuvant radiation therapy. Radiotherapy was delivered to the scar bed to a total dose of 22 Gy over 11 daily fractions. Acute radiotherapy toxicity necessitated a treatment break due to RTOG Grade III acute toxicity (moderate ulceration and skin breakdown) which resolved rapidly during a 3-day treatment break. The patient demonstrated local control and has remained free of local recurrence for more than 2 years. Conclusion: Radiotherapy for keloids represents a safe and effective option for post-surgical keloid therapy, especially for patients with bulky or recurrent disease. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.